

Appendix 2. Secondary endpoints of the study

- (1) Proportion of subjects who achieved a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of less than 7.5% at 24 weeks without dropout due to adverse events
- (2) 10-year-ASCVD risk change at 12 and 24 weeks compared to baseline
- (3) Ratio of subjects who achieved comprehensive lipid targets (low-density lipoprotein cholesterol [LDL-C] <70 mg/dL, non-high-density lipoprotein cholesterol [non-HDL-C] <100 mg/dL, and apolipoprotein B <80 mg/dL) without dropping out due to adverse events
- (4) Changes at 24 weeks compared to baseline for the following indicators
 - Calculated LDL-C, HDL-C, triglyceride, non-HDL-C, apolipoprotein B, apolipoprotein A1
 - Hepatic steatosis index
 - Fatty liver index
 - Non-alcoholic Fatty Liver Disease (NAFLD) liver fat score
 - Glycosylated hemoglobin
 - Fasting plasma glucose
 - sCD36
 - Homeostasis model assessment of insulin resistance
 - Homeostasis model assessment of β -cell function